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CHALLENGING SITUATIONS FOR PATIENTS WITH AGGRESSIVE LYMPHOMAS

Nancy L. Bartlett
Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO

Treating unfit patients with aggressive B-cell lymphoma poses the dilemma of balancing potential cure while minimizing
toxicity because of frailty and comorbidities. Age greater than 80 years and common comorbidities such as cardiovascular
disease and poorly controlled diabetes mellitus often preclude the use of full-dose anthracyclines and steroids, the
backbones of standard regimens for aggressive B-cell lymphomas. Assessing patient fitness remains subjective, with no
consensus on best practice or how to integrate assessment tools into decision making. Incorporation of prephase steroids
for all unfit patients may markedly improve performance status with consideration of standard dose therapy, especially in
patients less than age 80. Although randomized studies are lacking, current data suggest patients age ≥ 80 years are
considered unfit a priori and should receive dose-reduced anthracycline regimens or anthracycline-free regimens. Severe
toxicity is highest after the first cycle of chemotherapy. Dose reductions for cycle 1 in unfit patients with plans to escalate as
tolerated is often an effective strategy. Unfit patients often benefit from comanagement with gerontologists, cardiooncologists, and endocrinologists depending on age and the nature of comorbidities. Palliative therapy for patients with
newly diagnosed aggressive B-cell lymphoma results in median survivals of less than 3 months, and in general, should only
be considered in patients with untreatable comorbidities such as advanced dementia or refractory metastatic solid tumors.
Incorporating new, potentially less toxic agents such as novel antibodies, antibody–drug conjugates, and bispecific antibodies into first-line therapy is an exciting future direction with potential for substantial benefit in less fit patients.
LEARNING OBJECTIVES

• Compare the benefit of maintaining dose intensity in unfit patients with DLBCL aged <80 and ≥80
• Describe the outcomes with anthracycline-free regimens for unfit patients with DLBCL

Clinical case
An 84-year-old woman with a history of diabetes mellitus
(DM), chronic kidney disease, hypertension, atrial fibrillation, and diastolic dysfunction with preserved left ventricular ejection fraction (74%) presented with epigastric
pain, night sweats, early satiety, and a 5-lb weight loss.
Computed tomography scan revealed an 8.6-cm liver
mass, and a biopsy was consistent with diffuse large B-cell
lymphoma (DLBCL), germinal center B-cell (GCB) phenotype, with no evidence of MYC rearrangement. International prognostic index (IPI) was 4, performance status (PS)
was 2, lactic dehydrogenase level was 415 U/L, hemoglobin level was 9.7 g/dL, creatinine level was 1.48 mg/dL,
and brain natriuretic peptide level was 2700 pg/mL. Before her diagnosis, the patient was the full-time caregiver
for her husband, who has Alzheimer disease. The patient
and her family were considering palliative treatment options. Would you offer potentially curative therapy? If so,
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what are the chemotherapy options and what information
can you provide the patient regarding prognosis, possible
complications, and treatment-related mortality (TRM)?

Introduction
Patients with aggressive B-cell lymphoma who are unfit
represent a unique challenge, framed by the common
dilemma of whether to administer intensive therapy with the
potential for cure or to de-escalate therapy, thereby reducing toxicity.1 The aging population has led to a substantial increase in the number of older patients with DLBCL,
with 40% greater than 70 years of age, which is a group for
whom frailty and comorbidities limit options.2 Age greater
than 80 and common comorbidities such as cardiovascular
disease and DM often preclude the use of the standard
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), with prednisone, vincristine, and
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Approaches to aggressive B-cell lymphomas in less
fit patients

Assessment of patient fitness
Despite several proposed tools to assess patient’s baseline
status as fit, unfit, or frail, there is no uniform consensus on the
optimal tool, how to integrate tools into decision making,
and the impact of frailty assessments on patient outcomes.
Traditionally, comprehensive geriatric assessments are timeconsuming and often require consultation with a geriatrician.
This may be unrealistic for many patients with aggressive
lymphomas given the need to start treatment expeditiously and
the complexity of obtaining expedited referrals. The International Society of Geriatric Oncology task force reviewed several
screening tools to assess fitness and identified the G8 tool,
which includes only 8 questions and age, as one of the simplest
and most predictive assessments.6,7 The Charlson comorbidity
index, a weighted index that takes into account the number and
seriousness (scale of 0-5) of comorbid diseases, is commonly
used in assessing the extent and severity of comorbidities.8 More
recently, the Fondazione Italiana Linfomi group defined and
validated a new Elderly Prognostic Index integrating geriatric
and clinical assessment in 1353 patients age ≥ 65 years with
DLBCL using a simplified Comprehensive Geriatric Assessment
(sCGA) together with age to classify patients as fit, unfit, or frail
(Table 1).9 sCGA incorporates the activities of daily living (ADL)
score (1 point for bathing, dressing, toileting, transferring,
feeding, and continence), instrumental activities of daily living
(IADL) score (1 point for ability to use the phone, shop, prepare
food, keep house, do laundry, travel on public transportation,
handle money, and take own medication), and Comorbidity
Index Rating Scale.1,9,10 Multivariate analysis confirmed the
3 sCGA groups, IPI, and hemoglobin < 12 g/dL were independent
prognostic factors. Based on these independent factors, the

Table 1. Categorization of fitness and integration of age and
sCGA to define prognostic groups by the Fondazione Italiana
Linfomi
Fit

Unfit

Frail

ADL

6

5

≤4

IADL

8

7-6

≤5

CIRS-G

0 of score 3-4
<5 of score 2

Age

0 of score 3-4 ≥1 of score 3-4
5-8 of score 2 >8 of score 2

—

≥80 fit

≥80 unfit

Fit

Unfit

Frail

Age

<80

sCGA group

1

≥80
2

<80

≥80
3

CIRS-G, comorbidity index rating scale for geriatrics.
Reprinted from Spina et al9 with permission from the American Society of
Hematology.

Elderly Prognostic Index defined 3 groups of patients with a
3-year overall survival (OS) of 87% in the low-risk (0-1) group,
69% in the intermediate-risk group (2-4), and 42% in the high-risk
group (5-7). Importantly, this model categorizes all patients
age ≥ 80 as unfit or frail. Efforts are ongoing to develop an even
simpler but meaningful geriatric assessment tool, sometimes
referred to as a frailty vital sign, such as gait speed or grip
strength that can be easily incorporated into routine physical
examination.11,12
Use of even these simplified tools is uncommon in routine
practice, because of time constraints and lack of data on how to
incorporate the results into decision making. In a prospective
trial of 100 patients age ≥ 70 years with DLBCL, Spina et al1
prescribed modulated chemotherapy based on the sCGA. Patients scoring less than 5 on either the ADL or iADL scale had a
50% dose reduction and those scoring 5 on the ADL scale or 5 to
6 on the iADL scale had a 25% dose reduction, with excellent
outcomes and low toxicity rates reported. Despite the lack of
randomized or confirmatory trials, these guidelines represent a
reasonable quantitative approach to dosing for unfit patients.
Quantifying ADL and IADL scores, as well as a mini-mental status
examination score as standard practice, both at baseline and
intermittently on therapy, would potentially allow objective
guidance for dose escalation or de-escalation during subsequent cycles.

Prephase treatment
Treatment-related deaths in older patients undergoing chemotherapy for DLBCL occur most frequently after cycle 1. In a
retrospective study of 530 veterans age 80 and older treated for
DLBCL, there was an 18% TRM, with 67% (32 of 48) of deaths
associated with the first cycle of chemotherapy; most of these
were related to infection.13 PS at diagnosis was the most significant predictor of TRM: 27% in patients with a PS of 2 to 4 vs
8% in patients with a PS of 0 to 1. Prephase treatment was first
introduced by the German High-Grade NHL Study Group in the
NHL-B2 trial when a high rate of infection and death after the first
cycle of CHOP chemotherapy was noted in older patients on the
study.14 A trial amendment required a single injection of 1 mg
vincristine and 5 to 7 days of prednisone, 100 mg daily, before
Practice patterns for adults with AML | 141
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doxorubicin each posing special risks to vulnerable patients.3
Although many comorbidities may be manageable during chemotherapy, especially with the support of endocrinologists,
cardio-oncologists, and gerontologists, others such as advanced
dementia or concurrent metastatic solid tumor may prohibit
curative intervention for lymphoma. Guidelines for best practices
for unfit patients continue to rely on single arm phase 2 studies, as
well as retrospective and population-based data. The European
Society for Medical Oncology recently released recommendations for the clinical management of elderly patients with aggressive lymphoma that provide general guidance applicable to
less fit patients.4 Decisions about whether to treat unfit patients
with an anthracycline-based vs anthracycline-free regimen, and
when to dose reduce, are complex and driven by concerns that
comorbidities, impaired marrow function, poor PS, and impaired
nutritional status will contribute to more frequent treatmentrelated complications.5 Clinical trials often exclude the oldest
and least fit patients, and no prospective randomized studies have
addressed the appropriate regimen for this population. Additional
challenges include the complexity and often labor-intensive nature of formal comprehensive assessments needed to categorize
fitness accurately, as well as the lack of data to support use of
these objective tools in medical decision making. This article will
summarize treatment options for unfit patients with aggressive
B-cell lymphoma including the use of prephase steroids and other
supportive care measures, review data on the effect of dose intensity in older and less fit patients, and discuss strategies for
choosing a regimen that optimizes efficacy while minimizing
toxicity.

with gastrointestinal involvement by aggressive lymphoma,
prephase steroids may also decrease the risk of perforation and
improve outcomes.20 Despite the lack of randomized trials, there
seems little downside to prescribing 5 to 7 days of prednisone,
60 to 100 mg/day for all unfit or older patients before initiating
chemotherapy. Delaying decisions regarding dose reductions
until re-evaluation of PS after prephase steroids may allow a
subset of previously unfit patients to transition to standard
dosing.

Anthracycline-based chemotherapy

initiating CHOP. As shown in Figure 1, introduction of prephase
treatment significantly decreased the incidence of TRM in the
first 2 cycles.15 Although not quantified, Pfreundschuh15 also
describes a lower incidence of tumor lysis after the addition of
prephase treatment. In subsequent studies, the German HighGrade NHL Study Group eliminated vincristine and prescribed
only prephase prednisone. Peyrade et al16 incorporated vincristine 1 mg on day 7 and prednisone 60 mg on days 7 to 4 as
prephase treatment in the ofatumumab miniCHOP study for
patients age ≥ 80 with DLBCL, favoring a lower dose of steroids
because of the increased risk of mania, psychosis, and hyperglycemia in patients over age 80. In this study, 5% of patients
died on treatment, but none were treatment related, compared
with the prior rituximab plus reduced-dose doxorubicin, cyclophosphamide, vincristine, and prednisone (R-miniCHOP)
study, in which 27 of 150 (18%) of patients died on treatment,
with 8% (12 of 150) due to treatment-related toxicity, mostly
during cycles 1 and 2.16,17 Other small series, not limited to older
patients, have confirmed an improvement in PS and decrease in
first cycle admissions with prephase treatment.18,19 In patients

Figure 2. PFS in patients older than 80 years treated with R-miniCHOP (n = 150). Reprinted from Peyrade17 with permission of Elsevier.
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Figure 1. Therapy-associated deaths in the NHL-B2 trial of
CHOP in DLBCL before and after the introduction of prephase
treatment. Before ( ) and after ( ) the introduction of prephase
treatment. Reprinted with permission. Reprinted from Pfreundschuh14 with permission of the American Society of Hematology.

For patients without cardiac contraindications, anthracyclinecontaining regimens remain the standard of care.21 Lin et al21
identified 9 retrospective cohort studies and 2 SEER-database
derived analyses comparing chemotherapy regimens with and
without anthracyclines in more than 11 000 elderly patients with
DLBCL. With the limitations of inherent selection bias and the
lack of objective assessment of fitness, collectively, these
studies support an association between use of anthracyclinecontaining regimens and improved OS (3-year OS, 63% vs 44%)
with acceptable toxicities.21 Several other retrospective studies
have tried to evaluate outcomes with and without anthracyclines based on measures of fitness. In a retrospective analysis of
135 patients with DLBCL ages 60 to 84, 53 (38%) were classified
as unfit using CGA criteria.22 Among patients treated with curative intent, 1-year progression free survival (PFS) was 83.7% for
fit vs 66.5% for unfit patients (P = .011), with unfit patients having
higher IPI scores. Outcomes for patients treated with palliative
intent were dismal.
In an attempt to improve the tolerability of anthracyclinebased regimens in the oldest patients, a large single-arm phase 2
study tested R-miniCHOP in 149 patients over age 80 with
previously untreated DLBCL.17 R-CHOP dose modifications included doxorubicin 25 mg/m2, cyclophosphamide 400 mg/m2,
vincristine 1 mg, and prednisone 40 mg/m2, but no prophylactic
growth factors. The 2-year OS was 59% and 2-year PFS was 47%,
with 12 (8%) treatment-related deaths (Figure 2). An IADL score
less than 4 was predictive of outcome in univariate but not
multivariate analysis. A follow-up study by the same group explored ofatumumab-miniCHOP in a similar patient group and

reported a 2-year OS of 64.7% and PFS of 57.2% with no
treatment-related deaths.16 In addition to adding prephase steroids, this study incorporated documentation of a simplified
4-question IADL, Buzby nutrition index, and Charlson Comorbidity
score; however, the only factor predictive of outcome was the IPI
score. These regimens have not been tested in patients age less
than 80.

Impact of dose intensity based on age and fitness

Figure 3. Impact of intended and relative dose intensity of
R-CHOP in patients ≥ 70 years with DLBCL in a representative,
consecutive cohort across 8 UK centers (2009-2018) treated
with curative intent. (A) OS and (B) PFS by age and intended
dose intensity. Reprinted from Eyre24 with permission of the
Journal of Internal Medicine.

risk stratification before treatment if feasible.26 Following cardiac biomarker measurements (troponin and brain natriuretic
peptide) on treatment may ameliorate cardiotoxicity by allowing earlier intervention.26

Anthracycline-free regimens
Although regimens that do not include anthracyclines are
considered most commonly for patients with cardiovascular
comorbidities, a group of patients commonly excluded from
trials, this approach may also be appropriate for patients greater
than 80 years of age who are unfit. Anthracycline-free regimens
have been associated with a higher risk of death in patients with
age 75 to 79 regardless of comorbidities and in fit patients with
age 80 to 84.2 However, in patients with ages 80 to 84 years who
were unfit, or patients with age 85 years or older regardless of
comorbidities, outcomes without anthracyclines were not inferior to standard treatment.1
When anthracyclines are contraindicated, one approach is to
simply omit the doxorubicin and administer R-CVP (rituximab,
Practice patterns for adults with AML | 143
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Several retrospective series have attempted to address the
impact of dose intensity in older, unfit, and frail patients with
DLBCL. In a prospective study incorporating the CGA tool in 173
consecutive newly diagnosed patients age ≥ 70 treated during a
1-year period, curative treatment defined as >70% of the full-dose
intent to treat resulted in improved outcomes in the 16% of patients
categorized as unfit with a 2-year OS of 75% vs 45%, (P = .32). This
was not the case in frail patients.10 In an Asian population of
192 patients greater than age 60 with DLBCL, a PS of 2, age ≥ 75
years, and doxorubicin and cyclophosphamide relative dose intensity < 60% were all independent prognostic factors for survival.23
In 690 consecutive patients with age > 70 years with newly
diagnosed DLBCL treated between 2009 and 2018 across 8 UK
centers, the intended dose intensity <80% vs ≥80% in patients
with age 70 to 79 years was highly predictive of PFS and OS
(P < .001) but had no effect on outcomes in patients 80 or older
(P = .88; Figure 3).5,24 Comorbidities were associated with worse
OS, but not lymphoma-specific survival. Similar results were reported in another retrospective study of 142 patients treated at a
single medical center, with a marked reduction in OS for patients with
age <80 years receiving <90% of the recommended dose intensity of
doxorubicin (P = .005) or cyclophosphamide (P = .03), but not in
patients with age ≥ 80 years after controlling for IPI and albumin.25
In a population based Danish cohort study of 1011 patients
with age ≥ 75 years with DLBCL, the importance of dose intensity
was age dependent.2 Patients with ages 75 to 79, with or without
comorbidities, were better served by standard treatment with
R-CHOP than low-intensity (LI) treatment without anthracyclines.
In patients with ages 80 to 84 years with no comorbidities,
standard treatment also resulted in better PFS and OS than LI
treatment. However, after adjusting for baseline characteristics,
patients with age ≥ 80 years with comorbidities or patients with
age ≥ 85 years regardless of fitness did not benefit from standard
treatment over LI treatment. In all 3 age groups, palliative
treatment resulted in a median OS of 0.2 years.
In another population-based study, in 530 veterans age 80
and older with newly diagnosed DLBCL treated between 1998
and 2008, only 285 received systemic treatment, including 193
with an anthracycline-based regimen.13 Dose intensity ≥ 85%
was associated with worse outcomes compared with dose intensity < 85%. Particularly striking was a first cycle mortality of
11% in patients given full-dose doxorubicin compared with 2% in
those not treated with full dose. At 1 year, 59% of those treated
at full dose intensity were alive compared with 70% treated with
dose intensity < 85%; however, by 2 years, the OS rates were
53% vs 48%, perhaps suggesting higher relapse rates with lower
dose intensity. After controlling for other variables, anthracycline use was not associated with OS. The 40% of patients who
received no treatment had a median OS of 1.9 months.
If an anthracycline-based regimen is selected, a multidisciplinary approach including a cardiologist should be considered
for all unfit and older patients, with cardiovascular profiling and

One retrospective study of 81 patients (median age, 73 years) ineligible for R-CHOP had a 5-year time to progression of 57% after
treatment with R-CEOP.31 A single institution report of R-CEOP in
26 patients with a median age of 83 years reported 2-year event-free
survival and OS rates of 49% and 59%, respectively.32 An unexpected
finding in this small series was a 2-year PFS of 32% in the 13 patients
with a non-GCB phenotype compared with 80% in the 12 patients
with GCB phenotype (Figure 4B).
Other non–anthracycline-based approaches tested in the
front-line setting for unfit patients are regimens that are currently used in the DLBCL salvage setting. A phase 2 study of
R-GemOx (rituximab, gemcitabine, and oxaliplatin) was conducted in 60 patients with previously untreated DLBCL age 70 or
older, or age 60 to 69 with PS 2.33 At a median follow-up of
45 months, the 3-year PFS and OS were 49% and 65%, respectively. In multivariate analysis, only IPI score was a poor
prognostic factor, with 2-year OS of 38% in patients with IPI 3 to
5 compared with 85% for those with 0 to 2 (hazard ratio, 3.7).
Febrile neutropenia occurred in 8% of patients with no TRM. A
randomized trial is ongoing in China comparing R-miniCHOP to
R-GemOx in the frontline setting (NCT02767674).
Tolerability and effectiveness of the bendamustine rituximab
(BR) regimen in indolent lymphoma, stimulated evaluation of this
regimen, initially in relapsed DLBCL but more recently as first line
in older, less fit patients. In a phase 2 trial of 49 patients greater
than 70 years of age with DLBCL and significant comorbidities
(unfit and frail), the 2-year overall response rate was 62%, with
53% complete responses, but a disappointing 2-year PFS of
38%.34 In a retrospective comparison of BR vs R-CHOP in 140
patients ≥ 75 years of age, or >65 years of age with PS ≥ 2, BR was
associated with marked inferior median OS (16.3 vs 75.4 mo,
P = .006).35 BR patients were older and had higher-risk disease
but no difference in comorbidities or PS. In the subset of patients
with Charlson comorbidity index ≥ 6, there was no difference in
outcomes between BR and R-CHOP. Although the BR regimen is
well tolerated and has activity in DLBCL, the duration of remission in several reports appears significantly shorter that other
regimens in this setting.36,37 Table 2 summarizes outcomes with
the anthracycline- and non–anthracycline-based regimens discussed above in unfit and older patients.

Supportive care measures

Figure 4. PFS for R-GCVP and R-CEOP in patients not eligible for
R-CHOP. (A) PFS in patients (n = 63) considered unfit for anthracycline-containing chemoimmunotherapy because of cardiac comorbidity treated with R-GCVP. Reprinted from Fields30
with permission of the American Society of Clinical Oncology.
(B) Median PFS from a single institution report of R-CEOP in
patients with DLBCL (n = 26) separated into GCB and non-GCB
phenotype. Reprinted from Rashidi32 with permission of Taylor &
Francis.
144 | Hematology 2020 | ASH Education Program

Supportive care measures are essential in older patients undergoing aggressive chemotherapy. In addition to specific
recommendations described below, there should be consideration of more frequent follow-up of older patients, especially
during the first 2 cycles of treatment. For example, assessing
patients weekly with blood counts and the need for hydration
or calorie supplementation may allow earlier intervention and
avoid life-threatening complications. For patients with DM,
engaging the primary physician or an endocrinologist to follow
blood sugar control closely during treatment may lessen the risk
of severe hyperglycemia related to prednisone.

Prophylactic antibiotics
As described above, increased rates of infection were observed
in a number of R-CHOP–based trials in elderly patients. The
German NHL study group noted an increased risk of grade 3 and
4 infections in the DENSE-R-CHOP14 trial, which enrolled patients
61 to 80 years of age.38 After the first 20 patients, acyclovir (daily)
and cotrimoxazole (twice a week) were added to the regimen,
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cyclophosphamide, vincristine, and prednisone). In multiple retrospective series of patients ≥ 80 years of age, results with R-CVP
are generally inferior to R-CHOP, in large part likely because of
selection bias.27-29 Replacing doxorubicin with an alternative active, but less toxic agent, such as etoposide or gemcitabine, is also
an option. A phase 2 multicenter trial of R-GCVP (rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone),
accrued 61 patients (median age, 76.5 years) with newly diagnosed DLBCL and cardiac comorbidities.30 Overall response rate
was 61.3%, 2-year PFS was 49.8%, and 2-year OS was 55.8% with
no significant difference in outcomes for patients with left ventricular
ejection fraction >50% vs ≤50% (Figure 4A).30 Common grade ≥3
toxicities included hematologic (55%), infection (27%), and cardiac
(16%), with 3 fatal cardiac events on treatment. In the R-CEOP
(rituximab, cyclophosphamide, etoposide, vincristine, and prednisone) regimen, doxorubicin is replaced by etoposide (50 mg/m2
intravenously on day 1 and 100 mg/m2 orally on days 2 and 3).31,32

Table 2. Clinical trials with elderly/unfit patients with DLBCL

Patients, n

Median
age, y

Patients
age ≥ 80, %

ORR, %

CR, %

PFS, %

OS, %

TRM, %

Grade 3-4
F/N, %,

Reference

R-miniCHOP

II

150

83

100

73

62

47 (2-y PFS)

59 (2 y)

8

6

17

Ofa-miniCHOP

II

120

83

100

68

56

57 (2-y PFS)

65 (2 y)

0

21

16

R-GCVP

II

61

76

26

61

29

50 (2-y PFS)

56 (2 y)

7

0

30

R-CEOP

Retro

81

73

NR

NR

NR

57 (5-y PFS)

49 (5 y)

4

NR

31

Retro

26

83

65

75

58

49 (2-y PFS)

59 (2 y)

4

19

32

R-Benda

II

45

81

NR

62

53

38 (2-y PFS)

51 (2 y)

0

2

34

R-GemOx

II

60

75

27

75

47

49 (3-y PFS)

65 (3 y)

0

5

33

CR, complete response; F/N, febrile neutropenia; NR, not reported; ORR, overall response rate; Retro, retrospective study.

and the serious infection rate dropped from 35% to 18%. This rate
was also substantially lower than the 28% reported in a similar
patient population treated with standard R-CHOP-14, leading the
German NHL study group to recommend this prophylaxis in all
older patients receiving an R-CHOP regimen.15,38 Although no
consensus guidelines exist for antibiotic prophylaxis in less fit
patients with aggressive lymphoma, it is reasonable to consider
acyclovir and cotrimoxazole.

Myeloid and erythroid growth factors
Prophylactic myeloid growth factors should be considered for
all patients 80 years or older and those with significant comorbidities receiving cytotoxic chemotherapy for aggressive
lymphomas, regardless of the regimen. Growth factors were not
administered prophylactically in the R-miniCHOP regimen, and
the incidence of febrile neutropenia was only 7%; however, 3 of
149 (2%) of patients died of neutropenic sepsis during cycle 1.17
The American Society of Clinical Oncology guidelines recommend the use of myeloid growth factors for regimens with
a ≥20% incidence of febrile neutropenia; however, data used to
develop these guidelines would have included few patients age
80 and older and few unfit or frail patients.39 I favor erring on the
side of administering growth factors, particularly for cycle 1, in
this patient population, even if administering a less intensive
regimen.
Current guidelines do not recommend erythropoietin for
patients with curable cancers because of concerns of increased
thromboembolic complications and increased risk of progression in certain malignancies. A large randomized trial of darbopoeitin vs placebo in older patients with DLBCL receiving
R-CHOP showed no detrimental effect of darbopoeitin on PFS or
OS.40 A large meta-analysis also suggested the relative safety of
these agents in lymphoma.41 Importantly, many centers limit
transfusions to patients with hemoglobin less than 7 or 8 g/dL,
which may lead to more symptoms in patients over age 80 or
those with significant comorbidities. Even with less intense
regimens such as ofatumumab-miniCHOP, 15% of patients
required transfusions. 16 Based on individual patient circumstances, erythropoietin could be considered in the very
elderly or unfit who are experiencing significant treatmentrelated anemia.

Vitamin D supplementation
Although difficult to prove causality, several studies have shown
worse outcomes for a number of cancers in patients with low

vitamin D levels. A retrospective evaluation of pretreatment
serum samples from 359 patients 61 to 80 years of age with
DLBCL treated on the RICOVER-60 trial, showed that 54% were
vitamin D deficient (<10 ng/mL) and 46% were insufficient (1030 ng/mL).42 In contrast to the United States, there is no vitamin
D fortification of milk in Germany, perhaps accounting in part for
the remarkably high incidence of vitamin D deficiency in this
patient population. In a multivariate analysis, both event-free
survival and OS were significantly worse in patients with vitamin
D levels ≤8 ng/mL compared with those with levels >8 ng/mL.
Interestingly, there was no difference in patients who did not
receive rituximab, supporting the hypothesis that vitamin D
enhances rituximab-mediated cellular cytotoxicity.43 Vitamin D
supplementation to maintain levels >30 ng/mL is recommended
in this particularly vulnerable population.

Conclusions and future directions
Evidence-based guidance for treating less fit patients with
aggressive B-cell lymphoma is limited. Available data suggest
that patients ≥ 80 years of age and those with significant limitations of ADLs and IADLs do not benefit from full-dose chemotherapy and should be treated with R-miniCHOP or an
anthracycline-free regimen. Prephase steroids should be considered for all unfit and older patients, and decisions regarding
treatment should be reassessed based on PS after prephase. In
unfit patients, I start with a 25% to 50% dose reduction for cycle
1, and in those younger than 80 years of age, I attempt to escalate to at least 75% of standard dose with subsequent cycles if
tolerated.
Returning to the earlier case presentation, I recommended
R-CEOP with prophylactic pegfilgrastim for this 84-year-old
woman with high-risk, GCB phenotype DLBCL after describing the very poor survival with palliative approaches and an
approximately 40% to 50% chance of cure with a 5% to 10% TRM
using chemotherapy. Although I did not administer prephase
steroids, in retrospect, I should have. After cycle 1, she was
hospitalized for 2 weeks because of volume overload with
marked lower extremity edema, hyperglycemia requiring initiation of neutral protamine Hagedorn and sliding scale insulin
per endocrinology consult, and a gastrointestinal bleed. The
edema and hyperglycemia continued to be problematic throughout
treatment; however, she was able to complete 6 cycles at full
dose. Although end-of-treatment positron emission tomographycomputed tomography was interpreted as a partial response, she
Practice patterns for adults with AML | 145
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